US 12,419,201 B2
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
Fernando Jose Rebelo do Couto, Pleasanton, CA (US); Zhiming Liao, Livermore, CA (US); Andrea Muranyi, Tucson, AZ (US); Kandavel Shanmugam, Oro Valley, AZ (US); Shalini Singh, Tucson, AZ (US); and Yifei Zhu, San Jose, CA (US)
Assigned to Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed by Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed on Jul. 12, 2023, as Appl. No. 18/351,374.
Application 18/351,374 is a division of application No. 16/949,252, filed on Oct. 21, 2020, granted, now 11,747,339.
Application 16/949,252 is a division of application No. 15/851,502, filed on Dec. 21, 2017, granted, now 10,852,304, issued on Dec. 1, 2020.
Application 15/851,502 is a continuation of application No. PCT/EP2016/064883, filed on Jun. 27, 2016.
Claims priority of provisional application 62/186,251, filed on Jun. 29, 2015.
Prior Publication US 2024/0027463 A1, Jan. 25, 2024
Int. Cl. C07K 16/00 (2006.01); C07K 16/22 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/57496 (2013.01) [C07K 16/22 (2013.01); C07K 16/30 (2013.01); C07K 2317/20 (2013.01); C07K 2317/34 (2013.01); C07K 2317/92 (2013.01); G01N 2333/485 (2013.01)] 25 Claims
 
1. An antibody or antibody fragment capable of specifically binding to amino acids 148-169 of SEQ ID NO: 1, wherein the antibody or antibody fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises the following hypervariable regions (HVRs):
(a) an HVR-H1 comprising SEQ ID NO: 2;
(b) an HVR-H2 comprising SEQ ID NO: 3; and
(c) an HVR-H3 comprising SEQ ID NO: 4; and
wherein the light chain comprises the following HVRs:
(h) an HVR-L1 comprising SEQ ID NO: 9;
(i) an HVR-L2 comprising SEQ ID NO: 10; and
(j) an HVR-L3 comprising SEQ ID NO: 11.